Skip to main navigation
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

Investor Relations

  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Quarterly and Annual Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR

Changing the scale of what’s possible…

Nautilus Biotechnology seeks to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. By integrating breakthrough innovations in computer science, engineering, and biochemistry we have designed a large-scale, single molecule proteomic analysis technology capable of delivering extreme sensitivity and scale.

 

By enabling an expansion of both the depth and breadth of proteomic studies, Nautilus’ technology has the potential to revolutionize how biological research is conducted, drugs are identified and developed, and human disease is treated.

Change
Volume
52 Week High
52 Week Low
Jan 29, 2023 5:35 PM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2022 before market open on Thursday,
Jan 26, 2023
Nautilus Biotechnology Expands to San Diego
Proteomics company opens new office in Southern California to facilitate ongoing research and team growth aimed at unlocking the potential of the proteome SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule
Jan 26, 2023
Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
Collaboration enables TGen to gain access to data generated on prototype versions of Nautilus’ next-generation proteome analysis platform to advance the study of a rare childhood cancer SEATTLE, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc.
Jan 19, 2023

View All

Events
Nautilus Q4 2022 Earnings Conference Call
Feb 23, 2023 at 8:30 AM EST
Webcast
Nautilus Q3 2022 Earnings Conference Call
Nov 1, 2022 at 8:30 AM EDT
Webcast
Capital One Spatial Biology & Proteomics Summit
Sep 28, 2022 at 11:30 AM EDT

View All

Sign-up for updates

Sign Up

Nautilus Biotechnology

 

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

 

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

Nautilus Biotechnology

 

linkedin      twitter

info@nautilus.bio
+1 (206) 333-2001

© 2023 Nautilus Biotechnology Inc.

Privacy Policy | Terms